Al Construction Company and Pfizer's merger agreement finally released before Thanksgiving. However,
as the history of the largest in the industry mergers and acquisitions
excited when Al built the company has quietly deployed another important
research and development agreement. The
company will work with pharmaceutical companies to develop a series of
Rugen autism, obsessive-compulsive disorder as the representative of the
central nervous system disease drugs. This may be Pfizer - Al built last big action before the companies formally fit?
The
company did not disclose too many details of cooperation, saying only
that this cooperation includes pharmaceutical companies paid to Rugen
unknown number of advances and milestone bonuses. In
return, the company will be able to build Al proof of concept study
phase of drug candidate molecules preferentially developed Rugen. In addition, the two sides did not disclose the same drug targets involved in the experiment. However, Al Jian said that this novel small molecule drug molecules
has shown good results in animal models of autism and
obsessive-compulsive disorder.
The
company also said that the cooperation with Rugen company reflects its
advocacy of "open science" model, which will help companies take full
advantage of innovative capabilities of other academic and industrial
partners. David
Nicholson, executive vice president of research and development, said
the company, currently in late stage clinical development of
breakthrough drugs more competitive and less and less choice, so we
chose the company started cooperation with Rugen development from
preclinical studies aimed at the future of energy autism, OCD patients more choices.
After reaching this agreement with Pfizer built in Al announced that its $ 160 billion merger of. And with the merger of the latter it is also one of this year's entire biomedical industry's most important events. The merger is expected to be completed by mid-2016. By then, it will produce a well-deserved biopharmaceutical giant.
没有评论:
发表评论